KR20230157973A - Tnf-유사 리간드 1a(tl1a)에 대한 인간화 항체를 포함하는 조성물 및 이의 용도 - Google Patents

Tnf-유사 리간드 1a(tl1a)에 대한 인간화 항체를 포함하는 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20230157973A
KR20230157973A KR1020237031689A KR20237031689A KR20230157973A KR 20230157973 A KR20230157973 A KR 20230157973A KR 1020237031689 A KR1020237031689 A KR 1020237031689A KR 20237031689 A KR20237031689 A KR 20237031689A KR 20230157973 A KR20230157973 A KR 20230157973A
Authority
KR
South Korea
Prior art keywords
tl1a
dose
antibody
weeks
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237031689A
Other languages
English (en)
Korean (ko)
Inventor
앨리슨 루오
로렌 오츠키
마크 매닝
로버트 페인
올리비어 로렌트
재닌 빌스보로우
브래들리 헨클
스테판 알 타간
Original Assignee
프로메테우스 바이오사이언시즈, 인크.
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메테우스 바이오사이언시즈, 인크., 세다르스-신나이 메디칼 센터 filed Critical 프로메테우스 바이오사이언시즈, 인크.
Publication of KR20230157973A publication Critical patent/KR20230157973A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020237031689A 2021-02-18 2022-02-17 Tnf-유사 리간드 1a(tl1a)에 대한 인간화 항체를 포함하는 조성물 및 이의 용도 Pending KR20230157973A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US63/150,825 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US63/180,892 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US63/226,037 2021-07-27
US202163285781P 2021-12-03 2021-12-03
US63/285,781 2021-12-03
PCT/US2022/016841 WO2022178159A1 (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Publications (1)

Publication Number Publication Date
KR20230157973A true KR20230157973A (ko) 2023-11-17

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031689A Pending KR20230157973A (ko) 2021-02-18 2022-02-17 Tnf-유사 리간드 1a(tl1a)에 대한 인간화 항체를 포함하는 조성물 및 이의 용도

Country Status (19)

Country Link
US (1) US20240309104A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294444A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506940A (cg-RX-API-DMAC7.html)
KR (1) KR20230157973A (cg-RX-API-DMAC7.html)
AU (1) AU2022223420A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016672A2 (cg-RX-API-DMAC7.html)
CA (1) CA3207817A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002424A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023011969A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230436A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000162A (cg-RX-API-DMAC7.html)
EC (1) ECSP23070237A (cg-RX-API-DMAC7.html)
GE (2) GEAP202416596A (cg-RX-API-DMAC7.html)
IL (1) IL305312A (cg-RX-API-DMAC7.html)
JO (1) JOP20230185A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023009622A (cg-RX-API-DMAC7.html)
PE (1) PE20231681A1 (cg-RX-API-DMAC7.html)
TW (1) TW202246322A (cg-RX-API-DMAC7.html)
WO (1) WO2022178159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
US20260216326A1 (en) * 2022-12-22 2026-07-30 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
EP4665767A2 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the bile duct
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN105814081B (zh) * 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
US10968279B2 (en) * 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN119735681A (zh) * 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TW202600603A (zh) * 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途

Also Published As

Publication number Publication date
BR112023016672A2 (pt) 2023-11-21
AU2022223420A1 (en) 2023-09-21
WO2022178159A1 (en) 2022-08-25
CR20230436A (es) 2023-11-01
CA3207817A1 (en) 2022-08-25
TW202246322A (zh) 2022-12-01
IL305312A (en) 2023-10-01
EP4294444A4 (en) 2025-04-16
JP2024506940A (ja) 2024-02-15
CL2023002424A1 (es) 2024-01-05
JOP20230185A1 (ar) 2023-08-09
DOP2023000162A (es) 2023-10-15
EP4294444A1 (en) 2023-12-27
GEAP202416596A (en) 2024-10-28
MX2023009622A (es) 2023-08-28
US20240309104A1 (en) 2024-09-19
GEAP202316354A (en) 2023-12-25
PE20231681A1 (es) 2023-10-19
ECSP23070237A (es) 2023-10-31
CO2023011969A2 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
TWI871367B (zh) 針對類-tnf配體1a(tl1a)之人類化抗體及其用途
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
US20240309104A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
US20250243289A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
WO2023009545A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
EP4646443A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors
KR20250160371A (ko) 항-tl1a 항체 조성물 및 피부 치료 방법
EP4665395A1 (en) Anti-tl1a antibody compositions and methods of treatment in the liver
WO2024173838A2 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
WO2024186859A2 (en) Anti-tl1a antibody compositions and methods of treatment for sarcoidosis
EP4665394A2 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
WO2024137353A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
WO2024148218A2 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
CN118059231A (zh) 包括针对tnf样配体1a(tl1a)的人源化抗体的组合物以及其用途
CN117202932A (zh) 治疗肺部的抗tl1a抗体组合物和方法
JP2026021381A (ja) Tnf様リガンド1a(tl1a)に対するヒト化抗体およびその使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230915

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250214

Comment text: Request for Examination of Application